Charlotte, North Carolina (February 1, 2006) – BurnsAdler Pharmaceuticals, Inc. announced today that it has entered into an agreement with Sigma Tau Pharmaceuticals, Inc. to promote the company’s Matulane® (procarbazine hydrochloride) branded product in Puerto Rico and the U.S. Virgin Islands. Matulane® is indicated for use in combination with other anticancer drugs for the treatment of certain cancers. The product was marketed globally by Roche before being acquired by Sigma-Tau.
